Product Description
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Head and Neck Cancer|Squamous Cell Carcinoma|Synovial Sarcoma|Peripheral Neuroectodermal Tumors, Primitive|Leiomyosarcoma|Sarcoma, Ewing|Rhabdomyosarcoma|Primitive Neuroectodermal Tumors|Uveal Melanoma|Non-Small-Cell Lung Cancer|Prostate Cancer|Pancreatic Cancer|Osteosarcoma|Hepatocellular Carcinoma|Adenocarcinoma|Liver Cancer|Male Breast Cancer|Embryonal Rhabdomyosarcoma|Neuroblastoma|Neuroendocrine Tumors|Wilms Tumor|Alveolar Rhabdomyosarcoma|Breast Cancer|Retinoblastoma|Hepatoblastoma|Soft Tissue Cancer|Embryonal Carcinoma|Colorectal Cancer|Kidney Cancer|Adrenocortical Carcinoma|Neuroendocrine Carcinoma|Small Cell Lung Cancer|Hemangiosarcoma|Alveolar Soft Part Sarcoma|Mesothelioma|Liposarcoma|Neurofibrosarcoma|Gliosarcoma|Peritoneal Cancer|Gastrointestinal Cancer|Large Cell Carcinoma|Bronchiolo-Alveolar Adenocarcinoma|Esophageal Cancer
Phase 1: Oncology Solid Tumor Unspecified|Pinealoma|Glioma|Hypertension|Anemia|Hyperglycemia|Neutropenia|Thrombocytopenia|Peripheral Neuroectodermal Tumors, Primitive|Sarcoma, Ewing|Primitive Neuroectodermal Tumors|Hepatocellular Carcinoma|Islet Cell Carcinoma|Neuroendocrine Carcinoma|Insulinoma|Glucagonoma|Carotid Body Tumor|Somatostatinoma|Carcinoma, Merkel Cell|Medullary Carcinoma|Carcinoid Tumor|Gastrinoma|Malignant Carcinoid Syndrome|Gastrointestinal Cancer|Neuroendocrine Tumors|Pancreatic Cancer|Paraganglioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCI-2011-03039 | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2018-08-15 |
50% |
2019-03-18 |
|
| BATTLE-FL | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-08-15 |
2019-03-19 |
Treatments |
|
| NCI-2011-01917 | P2 |
Completed |
Small Cell Lung Cancer |
2016-11-15 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| 10-C-0146 | P2 |
Completed |
Mesothelioma|Peritoneal Cancer |
2016-08-13 |
2019-03-19 |
Treatments |
|
| A Study in Non-Small Cell Lung Cancer | P2 |
Completed |
Squamous Cell Carcinoma |
2016-06-10 |
2022-03-13 |
Treatments |
|
| NCI-2011-02005 | P2 |
Completed |
Embryonal Rhabdomyosarcoma|Alveolar Rhabdomyosarcoma |
2016-06-01 |
2024-11-27 |
||
| NCI-2012-03186 | P1 |
Completed |
Hepatocellular Carcinoma |
2016-05-01 |
2019-03-19 |
Treatments |
|
| NCI-2011-01960 | P2 |
Terminated |
Bronchiolo-Alveolar Adenocarcinoma|Large Cell Carcinoma|Non-Small-Cell Lung Cancer |
2016-01-01 |
2019-03-18 |
Treatments |
|
| NCI-2011-02003 | P2 |
Completed |
Prostate Cancer|Adenocarcinoma |
2015-06-01 |
2019-03-19 |
Treatments |
|
| NCI-2011-02045 | P2 |
Active, not recruiting |
Gastrointestinal Cancer|Esophageal Cancer|Squamous Cell Carcinoma|Adenocarcinoma |
2014-07-15 |
2024-04-03 |
Primary Endpoints|Study Completion Date|Treatments |
|
| NCI-2010-02196 | P1 |
Completed |
Gastrinoma|Neuroendocrine Carcinoma|Paraganglioma|Pancreatic Cancer|Somatostatinoma|Carotid Body Tumor|Glucagonoma|Islet Cell Carcinoma|Malignant Carcinoid Syndrome|Medullary Carcinoma|Carcinoma, Merkel Cell|Insulinoma|Carcinoid Tumor|Gastrointestinal Cancer|Neuroendocrine Tumors |
2014-07-01 |
2019-03-19 |
Treatments |
|
| NCI-2011-01408 | P2 |
Completed |
Osteosarcoma |
2014-07-01 |
2019-03-19 |
Treatments |
|
| NCI-2012-01971 | P2 |
Completed |
Synovial Sarcoma|Primitive Neuroectodermal Tumors|Liposarcoma|Sarcoma, Ewing|Leiomyosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Hemangiosarcoma|Alveolar Soft Part Sarcoma|Osteosarcoma|Alveolar Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Gliosarcoma|Neurofibrosarcoma |
2014-04-01 |
2019-03-19 |
Treatments |
|
| NCI-2009-00665 | P2 |
Completed |
Breast Cancer |
2014-01-07 |
2023-04-20 |
Primary Endpoints|Treatments |
|
| NCI-2009-00284 | P2 |
Completed |
Male Breast Cancer |
2013-09-09 |
2019-03-22 |
Treatments |
|
| NCI-2011-01976 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2013-08-01 |
2019-03-19 |
Treatments |
|
| NCI-2009-00282 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-06-01 |
2019-03-18 |
Treatments |
|
| 2010-022674-14 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma |
2013-05-09 |
2022-03-13 |
Treatments |
|
| NCI-2009-01170 | P2 |
Completed |
Kidney Cancer|Peripheral Neuroectodermal Tumors, Primitive|Embryonal Carcinoma|Adrenocortical Carcinoma|Wilms Tumor|Neuroblastoma|Synovial Sarcoma|Embryonal Rhabdomyosarcoma|Primitive Neuroectodermal Tumors|Liver Cancer|Sarcoma, Ewing|Osteosarcoma|Soft Tissue Cancer|Retinoblastoma|Hepatoblastoma |
2013-04-01 |
2019-03-18 |
Treatments |
|
| NCI-2012-02912 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-04-01 |
2019-03-19 |
Treatments |
|
| NCI-2011-02228 | P2 |
Completed |
Uveal Melanoma |
2013-03-01 |
2019-03-19 |
Treatments |
|
| NCI-2011-01406 | P2 |
Completed |
Prostate Cancer|Adenocarcinoma |
2013-02-01 |
2019-03-19 |
Treatments |
|
| I5A-MC-JAEM | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2013-01-01 |
2019-03-19 |
||
| CP13-0813 | P1 |
Completed |
Thrombocytopenia|Neutropenia|Hyperglycemia|Hypertension|Anemia |
2012-12-01 |
2019-03-19 |
Treatments |
|
| NCI-2011-01910 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2012-10-01 |
2019-03-18 |
Treatments |